Diversity in Acinetobacter baumannii isolates from paediatric cancer patients in Egypt

Article English OPEN
Al-Hassan, L ; El Mehallawy, H ; Amyes, S G B (2013)
  • Publisher: Wiley-Blackwell
  • Journal: Clinical Microbiology and Infection, volume 19, issue 11, pages 1,082-1,088 (issn: 1198-743X)
  • Related identifiers: doi: 10.1111/1469-0691.12143
  • Subject: Infectious Diseases | Microbiology (medical)
    mesheuropmc: biochemical phenomena, metabolism, and nutrition | bacteria | polycyclic compounds

Acinetobacter baumannii is an important nosocomial pathogen, commonly causing infections in immunocompromised patients. It is increasingly reported as a multidrug-resistant organism, which is alarming because of its capability to resist all available classes of antibiotics including carbapenems. The aim of this study was to examine the genetic and epidemiological diversity of A. baumannii isolates from paediatric cancer patients in Egypt, by sequencing the intrinsic blaOXA -51-like gene, genotyping by pulsed-field gel electrophoresis and multi-locus sequence typing in addition to identifying the carbapenem-resistance mechanism. Results showed a large diversity within the isolates, with eight different blaOXA -51-like genes, seven novel sequence types and only 28% similarity by pulsed-field gel electrophoresis. All three acquired class-D carbapenemases (OXA-23, OXA-40 and OXA-58) were also identified among these strains correlating with resistance to carbapenems. In addition, we report the first identification of ISAba2 upstream of blaOXA -51-like contributing to high-level carbapenem resistance. This indicates the presence of several clones of A. baumannii in the hospitals and illustrates the large genetic and epidemiological diversity found in Egyptian strains.
  • References (27)
    27 references, page 1 of 3

    1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538-582.

    2. Turkoglu M, Mirza E, Tunccan OG et al. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality. J Crit Care 2011; 26: 460-467.

    3. El-Mahallawy H, Sidhom I, El-Din NHA, Zamzam M, El-Lamie MM. Clinical and microbiologic determinants of serious bloodstream infections in Egyptian pediatric cancer patients: a one-year study. Intl J Infect Dis 2005; 9: 43-51.

    4. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007; 5: 939-951.

    5. Heritier C, Poirel L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005; 49: 3198- 3202.

    6. Zarrilli R, Giannouli M, Tomasone F, Triassi M, Tsakris A. Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities. J Infect Develop Count 2009; 3: 335-341.

    7. Evans BA, Hamouda A, Towner KJ, Amyes SGB. OXA-51-like b-lactamases and their association with particular epidemic lineages of Acinetobacter baumannii. Clin Microbiol Infect 2008; 14: 268-275.

    8. Hamouda A, Evans BA, Towner KJ, Amyes SGB. Characterization of epidemiologically unrelated Acinetobacter baumannii isolates from four continents by use of multilocus sequence typing, pulsed-field gel electrophoresis, and sequence-based typing of blaOXA-51-like genes. J Clin Microbiol 2010; 48: 2476-2483.

    9. Opazo A, Sonnevend A, Lopes B et al. Plasmid-encoded PER-7 b-lactamase responsible for ceftazidime resistance in Acinetobacter baumannii isolated in the United Arab Emirates. J Antimicrob Chemother 2012; 67: 1619-1622.

    10. Kaase M, Nordmann P, Wichelhaus TA, Gatermann SG, Bonnin R, Poirel L. NDM-2 carbapenemase in Acinetobacter baumannii from Egypt. J Antimicrob Chemother 2011; 66: 1260-1262.

  • Metrics
    No metrics available
Share - Bookmark